Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcutis Biotherapeutics Q4 GAAP EPS $(0.72) Beats $(0.78) Estimate, Sales $13.53M Beat $11.34M Estimate

Author: Benzinga Newsdesk | February 27, 2024 06:52am
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.78) by 7.69 percent. This is a 38.98 percent increase over losses of $(1.18) per share from the same period last year. The company reported quarterly sales of $13.53 million which beat the analyst consensus estimate of $11.34 million by 19.28 percent. This is a 356.81 percent increase over sales of $2.96 million the same period last year.

Posted In: ARQT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist